Theranostics Market Report 2026

Theranostics Market Overview

• Theranostics market size has reached to $122.98 billion in 2025 • Expected to grow to $205.54 billion in 2030 at a compound annual growth rate (CAGR) of 10.9% • Growth Driver: Rising Cancer Prevalence Fuels Growth In The Theranostics Market • Market Trend: Advancements in Theranostics Enhancing Personalized Medicine through Innovative Clinical Trials • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Theranostics Market?

Theranostics is a medical field combining therapeutics and diagnostics into a single, integrated approach. It involves developing and applying diagnostic tests that not only detect diseases or conditions but also provide information to guide personalized therapeutic interventions. The main types of theranostics are listed by disease type, including neurological disorders, cardiovascular diseases, immunological disorders, oncology diseases, and others. Neurological disorders refer to a range of conditions that affect the brain, spinal cord, and nerves, resulting in various symptoms and impairments that are treated by theranostics to facilitate accurate diagnosis, monitor disease progression, and guide personalized treatment approaches. The diseases are treated by different theranostics technologies, including polymerase chain reaction, immunohistochemistry, in-situ hybridization, sequencing, and others, which are employed by end users such as hospitals and clinics, diagnostic laboratories, and others.

What Is The Theranostics Market Growth Forecast?

The theranostics market size is expected to see rapid growth in the next few years. It will grow to $205.54 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising investments in precision medicine, growing adoption of ai-driven diagnostic tools, expansion of theranostic applications in oncology, increasing integration of genomics into clinical practice, higher demand for personalized treatment outcomes. Major trends in the forecast period include increasing integration of diagnostics with targeted therapies, rising adoption of personalized medicine platforms, growing use of molecular imaging techniques, expansion of companion diagnostic development, enhanced focus on patient-specific treatment pathways.

Global Theranostics Market Segmentation

1) By Disease Type: Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Diseases, Other Diseases 2) By Technology: Polymerase Chain Reaction, Immunohistochemistry, In-Situ Hybridization, Sequencing, Other Technologies 3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users Subsegments: 1) By Neurological Disorders: Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Epilepsy 2) By Cardiovascular Diseases: Coronary Artery Disease, Heart Failure, Atrial Fibrillation, Hypertension 3) By Immunological Disorders: Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease, Psoriasis 4) By Oncology Diseases: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer 5) By Other Diseases: Infectious Diseases, Metabolic Disorders, Genetic Disorders

What Is The Driver Of The Theranostics Market?

The rising prevalence of cancer is expected to propel the growth of the theranostics market going forward. Cancer refers to uncontrolled cell growth, which impacts various organs and contributes to significant morbidity and mortality worldwide. Theranostics, the integration of therapeutics and diagnostics, offers promising potential in cancer and chronic disease management. This approach enables personalized and targeted treatments by combining diagnostic and therapeutic capabilities, presenting opportunities for innovation in the healthcare industry. Hence, the increase in number of cancer patients will contribute to the growth of the theranostics market. For instance, in August 2024, according to the Macmillan Cancer Support, a UK-based organization, reported that in 2024, more than 3 million people in the UK are living with cancer, this figure is projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the rising prevalence of cancer is driving the theranostics industry.

Key Players In The Global Theranostics Market

Major companies operating in the theranostics market are Abbott Laboratories, Agilent Technologies Inc., Beckman Coulter Inc., Thermo Fisher Scientific Inc, Astellas Pharma, Radiopharm Theranostics Ltd, Alpha-Theranostics, Cardio-Theranostics LLC, Curium, Theradiag, Cell Theranostics, F. Hoffmann-La Roche AG, GE HealthCare Technologies Inc, Qiagen NV, Foundation Medicine Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Siemens Healthineers, Advanced Accelerator Applications, AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Bristol-Myers Squibb Company, Danaher Corporation, Illumina Inc., Merck KGaA, Roche Diagnostics Corporation, PerkinElmer Inc.

Global Theranostics Market Trends and Insights

Major companies operating in the theranostics market are focusing on developing technologically advanced solutions, such as theranostics clinical trials, to enhance personalized medicine and improve patient outcomes by integrating diagnostics and therapeutics into a single treatment approach. Theranostics clinical trials are research studies that evaluate the combined use of diagnostic tests and targeted therapies to tailor treatment strategies for individual patients. These trials aim to determine the effectiveness of specific treatments based on patient-specific biomarkers, thereby enhancing personalized medicine. For instance, in May 2024, BAMF Health, a US-based cancer treatment center, launched the COMBAT Trial, officially titled “A Phase I/II Theranostic Study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for Identification and Treatment of GRPR-expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617” (NCT05633160). Key features include a rapid activation process through BAMF Health's BAMF RapAct program, which enabled the trial to launch in just seven weeks, and a focus on utilizing innovative radiopharmaceuticals targeting the Gastrin-Releasing Peptide receptor (GRPR), aiming to improve treatment options for patients with limited therapeutic avenues.

What Are Latest Mergers And Acquisitions In The Theranostics Market?

In March 2023, Radiopharm Theranostics, an Australia-based biotechnology company specializing in radiopharmaceutical products, acquired Pharma15 Corporation for $4 million. Through this acquisition, Radiopharm aims to explore the potential of next-generation radiopharmaceuticals for the treatment of prostate cancer, with a focus on surpassing PSMA-based therapies and advancing innovative solutions for patients. Pharma15 Corporation is a US-based pharmaceutical company that specializes in the development of radio-immuno-theranostic platforms and pharmaceutical products.

Regional Outlook

North America was the largest region in the global theranostics market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Theranostics Market?

The theranostics market consists of revenues earned by entities by providing genetic testing, targeted therapy services, contract development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The theranostics market also includes of sales of companion diagnostics, nanomedicine and 2D nano-theranostics materials. Values in this market are """"factory gate"""" values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Theranostics Market Report 2026?

The theranostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the theranostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.